Board of Directors Mr Iain Ross Chairman, Non-Executive Director...

Board of Directors
Mr Iain Ross Chairman, Non-Executive Director
Mr Bryce Carmine Non-Executive Director
Mr Steven Coffey Non-Executive Director
Ms Ebru Davidson, Non-Executive Director
Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000
ASX ANNOUNCEMENT
08 June 2023
KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO
INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE
2 & 3 GLIOMA
Sydney, 08 JUN 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-
focused drug development company, is pleased to announce that it is supporting the
University of Sydney on a molecularly-guided phase II clinical study to examine paxalisib in
adult patients with recurrent/progressive isocitrate dehydrogenase (IDH) mutant grade 2
and 3 glioma (G2/3 gliomas).
The study, named LUMOS2, will be sponsored by the University of Sydney, and coordinated
by NHMRC Clinical Trials Centre, University of Sydney, in collaboration with COGNO (Co-
Operative Trials Group for Neuro-Oncology).
The study team will be led by Professor Hui Gan, Co-Director, Centre for Research Excellence
in Brain Cancer and research clinician at the Olivia Newton-John Cancer Research Institute in
Melbourne, VIC, who specializes in the investigation of novel therapies for brain cancer.
Key Points
• The LUMOS2 study aims to investigate paxalisib and other targeted therapies in
adult patients with grade 2 or 3 IDH-mutant gliomas. Paxalisib is already the subject
of several studies in high-grade glioma, a category which includes diseases such as
glioblastoma and Diffuse Intrinsic Pontine Glioma (DIPG).
• Grade 2 and 3 gliomas represent a substantial unmet clinical need, with recurrent
patients having a poor prognosis that is comparable to glioblastoma. The glioma
patient population has been the subject of increasing focus for drug development
companies, including Day One Biopharmaceuticals (NASDAQ: DAWN), Servier and
Novartis (NYSE: NVS).
• LUMOS2, an umbrella study with multiple arms, is expected to enroll up to 76
patients and will be a multi-centre study at several Australian sites, with the
potential to expand internationally